Life Sciences Archive » August, 2012

Life Sciences - August, 2012

277 articles

• $12B Nestle-Pfizer Deal Could Impact Formula Market: Regulator
• Hospital Says Baxter Unit Can't Dodge Drug Pump Royalties
• GSK Hits Apotex With Suit Over Bid For Generic Prostate Drug
• Abbott Targets Amneal In Latest Fight Over Generic Niaspan
• Pharmacy Can't Force Cardinal Health To Supply Painkillers
• Upsher-Smith Urges High Court To Hear K-Dur Antitrust Case
• 4 Firms Feared Most By In-House Counsel
• Researchers Fire Back At University In IP, Contract Fight
• Taro's PE Backers Balk At Sun Pharma's $600M Buyout
• Biotech Co. Says BP Unit Conducted Negligent Enzyme Work
• Janssen Loses La. Appeal Of $258M Risperdal Verdict
• Novartis Wins Bone Drug Injury Suit On Timeliness
• FDA Questions Efficacy Of Novartis Inhaled CF Treatment
• High Court Grants Review Of CAFA Dispute
• Wyeth Loses Bid To Toss 2 Fen-Phen Suits
• Judge Guts Medline Suit Seeking Surgical Mesh Coverage
• Apotex, Lupin Hit With Suit Over Generic Arthritis Drug
• CBP Change: The Centers Of Excellence And Expertise
• Wyeth, Schwartz Ask 10th Circ. To Nix Suit Over Generic Reglan
• Sunovion To Lay Down Up To $430M For Elevation Pharma
• FTC Cephalon Case Stayed Pending K-Dur Supreme Court Bid
• Judge Trims Securities MDL Claims Against Merck Execs
• Bristol-Myers Recalls Cancer Drug Due To Overfilled Vial
• Wolters Kluwer Must Face Accutane Case In Pa. Court
• Pfizer Units Triumph In Latest Hormone Therapy Suit
• J&J To Pay States $181M Over Deceptive Risperdal Marketing
• Genmab Lands Potential $1.1B J&J Cancer Drug Deal
• Watson Next Target As Purdue Protects Insomnia Drug Patent
• Novartis Beats Zometa Injury Suit At 2nd Circ.
• Omnicare Skirts FCA Suit Over Anti-Psychotics Prescriptions
• GNC, USPLabs Hit With Suit Over DMAA Supplements' Safety
• Novo Still Owes $3M Over Patent Use Code Row, Caraco Says
• Pliva, Others Escape Generic Reglan Suit Due To Mensing
• Helicos Genetics Patent Ruled Invalid In Illumina Row
• MDL Plaintiffs Say GSK Won't Uphold Avandia Settlement
• Abbott Says Sandoz Marketed Generic Nimbex Too Soon
• FTC May Have To Follow Merck's Lead In Pay-For-Delay Fight
• SEC Sues 8 For Insider Trading In Sanofi, Chattem Deal
• Medex Can't Take Back 347 Emails From Discovery In $7M Suit
• FDA Warns Hospira Over Issues At Costa Rican Plant
• Janssen Again Targets Lupin, Others Over Generic Prezista
• FDA Advisers Back Broader Humira Approval
• UK Removes DMAA Weight-Loss Supplements From Market
• Sun Pharma Unit Back In Action 3 Years After Drug Seizures
• Sanofi's Genzyme Pulls 19 Lots Of Thymoglobulin Vials
• Danisco Targets Novozymes Ethanol-Producing Enzyme Patent
• Novartis Dodges Fraud Claims In Farmers' Pesticide Suit
• Authorized Generics And Pay-For-Delay Settlements
• Merck Moves To Block Generic Ganirelix Fertility Treatment
• Old Claims Off Limits In Supplement Co. CEO's Trial: 9th Circ.
• FDA Puts Idenix Hep C Drug On Hold Amid Bristol-Myers Woes
• Baxter Win Gives Drugmakers A Leg Up In NJ Warning Suits
• Pfizer Failed To Warn Of Azithromycin Side Effects, Suit Claims
• AstraZeneca, Others Hit With Nexium Pay-For-Delay Suits
• Bristol-Myers Sued Over Heart Damage In Hep C Drug Trial
• FDA To Study How Well Consumers Understand Pharma Ads
• Endo Claims No Liability In AMS Pelvic Mesh Implants MDL
• FSMA's Potential Impact, Part 3: Reinspection, Recall Fees
• Profit Counting: The Pfizer FCPA Settlement
• AstraZeneca Reaches $26M Deal With SC In Seroquel Suit
• GAO Backs Philips' Protest Of VA Imaging System Contract
• Merck Asks High Court To Review K-Dur Pay-For-Delay Case
• Method Patent, Lilly Drug Patent Can Coexist, Fed. Circ. Rules
• Chamber Backs Allergan's Appeal Of Controversial Decision
• Bristol Takes $1.8B Hit, Ditches Hepatitis C Drug After Death
• DC Circ. Upholds NIH Stem-Cell Research Funding
• Cipro Buyers Urge Calif. Court To Revive Pay-For-Delay Case
• Pfizer Strikes Deal With Impax Over Generic Detrol LA
• Evanston Wins 5th Circ. Coverage Row In Organ Selling Case
• Horizon Unit Closes $75M Loan For Health, Tech Investments
• Expert Report Sticks In P&G Denture Cream MDL
• EU Agency Demands Cancer Drug Recall Due To Sterility Risks
• FDA Wary Of Wider Use For Abbott's Humira
• What's Making Attorneys Flee Their Firms?
• Purdue Sues Actavis Over Patent For Generic Sleep Drug
• Pfizer Can't Boot Doctors' Suicide Testimony From Chantix MDL
• ViiV, Vertex Sue Over Mylan's Bid To Market Generic Lexiva
• New Context For Application Of State-Of-The-Art Principle
• PPACA: What's Next For Life Sciences Companies
• J&J's DePuy Recalls Joint Implants After FDA Warning Letter
• Pfizer, Others Shake Price-Fixing Appeal From Pharmacies
• Purchaser Class Certified In J&J Blood Test Antitrust MDL
• Pa. High Court Won't Bar Reglan Patients' Claims
• Customers Call Foul On Vitamin Co.'s Cartilage-Healing Claims
• USPTO Can't Dodge Exela Suit Over Patent Revival
• SEC's Conflict Minerals Rules: Strict, Onerous, Vague
• What You Need To Know About Chinese Product Liability Law
• Actavis Sued Over Generic Oleptro Plans
• ArthroCare Execs Arrested Over $400M Stock Drop
• Fed. Circ. Junks Boston Scientific Win In Stent Patent Fight
• Medtronic Fails To Beat Bone Device Claims On Preemption
• Device Co. Sues Over $6M Loss After Tainted Mouthwash Recall
• FDA Warns Generics Makers To Yank Defunct Applications
• Judge Reverses Consolidation Of Bayer FCA Suits
• Hatch-Waxman Safe Harbor: Post-Approval Activity Update
• Cardinal Subpoenaed By DEA, DOJ Over Drug Diversion
• Shire Says Genzyme Can't Prove False Bone Drug Claims
• Shoe Insert Maker Sued Over Whistleblower's Ouster
• Drug, Medical Device Tracking — Will Medications Be Next?
• Generics Safe Harbor Question Could Derail Biosimilars
• Drug Cos. Cut Loose From Darvocet, Darvon MDL Suits
• Merck Sues To Shut Out Watson's Generic Propecia
• FDA Warns Medtronic Unit Over Handling Of User Complaints
• Synthes Bone Putty Recalled Over Fire Risk During Surgery
• Gilead Hits Cipla With Patent Suit Over HIV Drug Emtriva
• Pfizer Tells 1st Circ. Neurontin MDL Shows No Proof Of Harm
• A Therapy For European Patent Term Extensions
• Del. Court Won't Toss Board Election Shareholder Suit
• FDA Ends Ban Of Claris Lifesciences Products
• Nutrition Co. Sues Beazley Over $1M In Hurricane Damages
• Patent Re-Exam Discovery Barred, Abbott Tells Fed. Circ.
• Biotech Exec Settles Over Trades Ahead Of Novartis Deal
• FDA Ties Post-Approval Device Studies To Public Health
• J&J Unit Settles 1st Metal Hip Implant Suit Slated For Trial
• Judge Kills Shareholder Suit Over J&J's $20B Synthes Buyout
• St. John's Settles Contract Suit Over Army Eye Research Deal
• Baseball Hall Of Famer Settles Insider Trading Claims
• US Joins FCA Suit Over Orthotics Co. Billing
• CMS Names New Chief To Implement Key ACA Provisions
• Amgen Ruling Placed Cert. Bar Too Low, Ex-SEC Officials Say
• Cinven To Pay HgCapital £465 Million For Drugmaker Mercury
• 3rd Circ. Keeps K-Dur Ruling In Place As FTC Fights IP Deals
• Bill Bolstering Calif. False Claims Law Heads To Gov.
• Myriad — Under The Microscope
• Medical Industry Fears Device ID Rule Would Drive Up Costs
• J&J Intermediary Drug Rule Case Won't Get 2nd Look
• Patent Law Trumps Policy In Myriad Cancer Gene Decision
• FDA Pushes X-Rays For St. Jude Heart Device Recipients
• Janssen Biotech, NYU Sued Over Neuro Treatment Patents
• J&J, Pfizer, Others Beat Pharmacies' Drug Pricing Suit
• New Patient Rep Law Could Shake Up Drug Review Process
• Senators Want Tighter Rules On Livestock Antibiotics
• Fed. Circ. OKs Myriad's Gene Patents In Light Of Prometheus
• GSK, Teva Say Lamictal IP Licensing Deal Wasn't Conspiracy
• Unveiled: A New Enforcement Method In GSK Settlement
• Reverse Payment Settlements In Pharma Industry: Revisited
• FTC's Pay-For-Delay Push May Hinder Pharma Patent Deals
• Santarus Seeks To Block Dr. Reddy's Generic Zegerid
• US Joins FCA Suit Over Off-Label Vein Treatments
• Lawmakers Urge FDA To Overhaul Medical Device Database
• Class Cert. Sought In Covidien Surgical Stapler Suit
• Codeine Can Be Deadly For Some Children, FDA Warns
• Quigley Ch. 11 Plan Heads To Vote Despite Protests
• HHS Recruits Pharmacies To Tout ACA's Medicare Benefits
• Pfizer Vaccine Decision In Federal Court Bars NJ Suit, Court Says
• Grassley Expands Agency Email-Monitoring Inquiry
• Watson Sues FDA To Regain Exclusivity For Generic Actos
• GSK Keeps Slimming Down With $270M Sale Of Aussie Drugs
• Omnicare Beats Contaminated-Drug FCA Suit
• Faulty Breast Implants Spark UK Cosmetic Surgery Probe
• 4th Circ. Clears Alpharma Of Ex-Sales Rep's Retaliation Claim
• Court Blocks Sale Of Blood Clot Reducer 'Knockoff'
• Bayer Seeks Centralization Of NJ Mirena Litigation
• Quigley, Pfizer Answer Disclosure Statement Objections
• Drug, Device Makers Push For Final Physician Payment Rule
• Roche Worker Axed For Resisting Hasty Cancer Trials, Suit Says
• Icahn Blasts Forest Labs' Nondisclosure Of FDA Letter
• Trademark Must Be Considered As A Whole, Fed. Circ. Rules
• Goodwin Procter Brings Former ITC Atty Into IP Group
• AstraZeneca Looks To Block Generic Pulmicort
• CMS Overpaid $4.6M For Drugs Last Quarter, Report Says
• J&J Unit Escapes FCA Case Over Alleged Procrit Kickbacks
• Drugmakers Freed From Generic Reglan Claims In Tenn. Suits
• Fed. Circ. Revives Jury Verdict In Wake Forest Patent Suit
• FTC's New Rule Zeroes In On More Pharma Patent Deals
• ACA Unlikely to Change Employer Health Coverage, GAO Says
• FTC Rips Wyeth, Teva Arguments In Effexor Antitrust Suit
• Former Hansen Medical VPs Can't Duck SEC's Fraud Claims
• Shearman Reps Sun Pharma In Long-Sought $600M Taro Buyout
• Ga. Medicaid Program Must Buy Brand-Name Makena: Judge
• Irish Drugmaker Elan To Spin Off R&D Business
• Drug Wholesaler Altec Fined $2M In Gray Market Conspiracy
• Establishing The Weight Of Evidence After Sciele
• Callisto Investor Challenges Proposed Synergy Merger
• Ohio Willow's Prosthetic-Cushion Patent Ruled Invalid
• Mensing Can't Keep Bristol-Myers' Plavix Suits Federal
• Vioxx Appeal Imperils Merck MDL Deals, 5th Circ. Hears
• New FDA Guidance Aims To Speed Medical Device Reviews
• Forest Labs To Alter Governance To Settle Derivative Suits
• Ex-China Official's Testimony Lends Boost To Vitamin C Cos.
• Ex-Carlyle Consultant Gets Probation For Insider Trading
• Sequester Could Gum Up FDA Drug, Device Reviews
• Breg Pain Pump Injury Case Revived In 6th Circ.
• Hansen Can't Escape Bulk Of Securities Inflation Class Action
• Hatch-Waxman Safe Harbor's Scope Likely Headed To High Court
• Roche Blockbuster Lucentis Gets FDA Nod For Broader Use
• CR Bard's Faulty Filters Pose Health Risks, Suit Says
• J&J Misrepresented Splenda Health Benefits, Suit Says
• Cumberland Seeks To Block Perrigo's Generic Acetadote
• Smith & Nephew Seeks $2M From Rivals In Noncompete Suits
• US Trustee Rips Pfizer Unit Quigley's Newest Ch. 11 Plan
• GSK Can't Use Prometheus To Nix Classen's Patent Suit
• No Need To Change Regs To Suit Nanotech Drugs: FDA Official
• GSK Hit With Thalidomide Birth Defect Suit
• Orthofix Bribed Doctors To Use Surgical Services, Suit Says
• NJ Court Keeps Some Claims Alive In Cordis Stent Case
• Forest Labs Reps Marketed Daliresp Off-Label, FDA Says
• Fed. Circ. Eyes Roche's Bid To Stop Boniva Generics
• Judge Orders FDA To Launch Livestock Antibiotic Withdrawal
• Stryker Hit With 1st Metal Hip Implant Suit Since Recall
• Judge Potentially Limits Claims in Avandia MDL
• FDA Limits Use Of Stryker's Wingspan Anti-Stroke Stent
• Limitation On Future Patent Protection For Biosimilars?
• K-V Pharma Wins Access To $31M In Cash Collateral
• Ex-Pfizer CEO Kindler Joins Health Care VC Firm Lux
• FDA Admits It Has Yet To Fill In Big Gaps On Biosimilar Regs
• Generics Industry Gets FTC OK For Shortage Prevention Plan
• Novartis Keeps Grip On Eye Drug Patent In Fed. Circ.
• Former Home Diagnostics CEO Admits To Insider Trading
• K-V Bankruptcy May Hurt FDA's Unapproved Drug Initiative
• 2 North China Pharma Units Exit Vitamin C Antitrust MDL
• Patients Say GSK Lyme Disease Vaccine Caused Arthritis
• Neurontin Ruling Would Kill Off-Label Use, 1st Circ. Hears
• Rule-Of-Reason Analysis Of Pay-For-Delay Settlements
• Warner Chilcott To Pay $1B In Dividends Instead Of Sale
• K-V Challenge To FDA's Enforcement Order On Thin Ice: Judge
• Roche Could Wield Fla. Law Ruling In Other Accutane Suits
• Barr Uses Mensing To Escape Generic Accutane Case
• Judge Triples Damages, Bars Sales In Zeiss Lens Patent Suit
• Medicare Contractors Overpaid $1.6M For Cancer Drug: OIG
• Vaccine Buyers Allowed To Bring Antitrust Suit Against Sanofi
• Epstein Lands GE Expert On Health Tech For LA, DC Offices
• BC Partners Puts Up €500M For German Drugmaker
• Proskauer Hires NetBio GC As Patent Partner In NY Office
• Pfizer Will Pay $60M To End Foreign Bribery Probes
• Much Ado About The Crime Of Doing Nothing
• Bankruptcy Judge Grants K-V Pharma Most 1st-Day Motions
• Bristol-Myers Insider Trading Suit Is Compliance Gut Check
• Manufacturer Can't Shake NuAire's Incubator Recall Case
• J&J Win Affirmed In 5th Circ. Mesh Warning Appeal
• CORRECTED: Rival Drug Didn't Infringe Genzyme's Arthritis Patent: Jury
• Pharmas Seek Pay-For-Delay Suit Stay Pending High Court Input
• K-V Files For Ch. 11 As $45M Hologic Bill Comes Due
• Paul Floats Bill To Allow Dying Access To Unapproved Drugs
• 9th Circ. At Odds With Calif. Law In OT Case, Drug Reps Say
• J&J's Birth Control Warnings To Doctors Were Enough: Ruling
• FDA Feedback: New Guidance For Device Applicants
• Avoiding Trade Secret Litigation In The Life Sciences
• Case Study: In Re Boston Scientific
• Nycomed, Others Say Apotex Infringes Nasal Spray Patents
• University Says Cancer Research Team Defected, Stole IP
• JPML Won't Centralize Drug Co-Pay Coupon Class Actions
• New Clinical Trial Reporting Bill Risks Spooking Investors
• High Court Could Upend Rare Post-Mensing Loss For Generics
• SEC Targets Teva In FCPA Compliance Probe
• Bristol-Myers Exec Dug Own Grave With Cover-Up Efforts
• Fed. Circ. Lifts Sales Ban On Generic Lovenox
• Aredia, Zometa MDL Judge Moves To Speed Up Cases
• Certifying Compliance Doesn't Decide FCA Burden, US Says
• 8th Circ. Reopens Suit Over Cymbalta Suicide Risks
• Surgical Robot Injury Suits Against Intuitive Won't Be Merged
• Sanofi Accord Brings Idaho Price-Inflation Haul To $23M
• J&J Settles Risperdal Marketing Claims From DOJ, States
• Sanofi Win Marks Another Step In Drugmakers' Twombly March
• Judge Mulls Stay In Roche's Xeloda Patent Suit Against Teva
• Diet Aid Co.'s Insurance Claim Not Time-Barred, 5th Circ. Told
• Class Says It Was Burned By Misleading Coppertone Ads
• Ostrolenk Faber Loses Bid To Reclaim Fees From Biotech Co.
• US Gets Devices To Market Faster Than Europe, Study Shows
• Sens. Want Detailed Cost-Benefit Studies For New Regs
• Ex-Biosara CEO Sues For Return Of 6M Shares
• Covidien Says AECOM Overcharged On Nuke Cleanup Contract
• Merck Gets Claims Based On Puffery Trimmed From Vioxx Suit
• Bristol-Myers Squibb Exec Accused of Insider Trading
• The Evolving Patent Term Adjustment Landscape
• Polsinelli Pulls Pharmaceutical IP Trio To NY Office
• Medical Device Co. Medeia Accuses Rival Of Lifting Software
• Olympus Tells DOJ Of Possible FCPA Violations In Brazil
• Class Cert. In Bayer Case Threatens Due Process, Group Says
• NJ Court Backs Toss Of NuvaRing Suit Against Organon
• Another Co. Surrenders In Seroquel XR Patent Fight
• DSM Sues Supplier Over Recall Due To Unlisted Milk Allergen
• FDA Finalizes Electronic Registration Rule For Devices
• BMS Sues Mylan For $15M Over Improper HIV Drug Sales
• McDermott Boosts Life Sciences Practice With 2 Attys
• Fired Med. Device Worker Didn't Show Retaliation: 8th Circ.
• Matrixx Investors Get Class Cert. In Suit Over Zicam Effects